# Blood glucose performance test

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>		
10/02/2017	Recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
12/05/2017	Ongoing	Results		
Last Edited	Condition category	Individual participant data		
09/07/2020	Nutritional, Metabolic, Endocrine	<ul><li>Record updated in last year</li></ul>		

#### Plain English summary of protocol

Background and study aims

Diabetes is a lifelong condition that causes a person's blood sugar (glucose) level to become too high. The aim of this study is to monitor the performance of blood glucose monitoring systems (blood glucose meters and test strips) designed for people with diabetes to test their blood glucose.

Who can participate?

Patients aged 16 and over with diabetes

#### What does the study involve?

Participation for the patient consists of one visit to the study site. The visit is expected to last about 5 to 20 minutes. The participant gives a blood sample either by venepuncture (the puncture of a vein) or by a fingerprick and the blood is tested using both the blood glucose monitoring system and the reference method. The accuracy and precision of the methods are compared.

What are the possible benefits and risks of participating?

There may be no direct benefit to the participant taking part in this study. However, the information gained from the results ensures the blood glucose monitoring systems provide reliable results. The only risks of participating in this study are associated with blood sample collection. These are small but could include pain, bruising, local infection and fainting.

Where is the study run from?

- 1. Ipswich Hospital (UK)
- 2. Oxford Centre for Diabetes, Endocrinology and Metabolism (UK)
- 3. St James's University Hospital (UK)
- 4. Salford Royal Hospital (UK)
- 5. North Manchester General Hospital (UK)

When is the study starting and how long is it expected to run for? February 2017 to December 2029 (updated 16/07/2019, previously: July 2027)

Who is funding the study? Abbott Diabetes Care Ltd (UK)

## Contact information

#### Type(s)

**Public** 

#### Contact name

Dr Pamela Reid

#### Contact details

Range Road Witney United Kingdom OX29 0YL +44 (0)1993 863024 Pamela.reid@abbott.com

## Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

## Secondary identifying numbers

ADC-UK-PMS-16030

# Study information

#### Scientific Title

Blood glucose performance test: a multi-centre prospective single-arm study

#### **Study objectives**

Assess the accuracy of blood glucose monitoring systems using capillary blood samples according to ISO 15197 and venous blood samples using the Consensus Error Grid.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

NRES Committee: London – Westminster Research Ethics Committee, 22/12/2016, ref: 16/LO /2217

## Study design

Multi-centre prospective single-arm study

#### Primary study design

Interventional

## Secondary study design

Non randomised study

#### Study setting(s)

Hospital

#### Study type(s)

Diagnostic

#### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

#### Health condition(s) or problem(s) studied

Diabetes mellitus

#### **Interventions**

Whole blood obtained from the subject (venous whole blood from venepuncture or capillary whole blood from a fingerstick) will be tested on the blood glucose monitoring systems, the HemoCue analyser and the YSI analyser.

#### Intervention Type

Device

#### Primary outcome measure

- 1. The accuracy of the blood glucose monitoring system compared to the YSI analyser using fingerstick capillary or venous whole blood samples:
- 1.1. Capillary: Percentage of replicates within ISO15197 2003 or 2015 system accuracy criteria
- 1.2. Venous: Percentage of responses within each zone of the Consensus Error Grid Measured at the single study visit

## Secondary outcome measures

- 1. Precision: Mean paired replicate coefficient of variation (Capillary/Venous)
- 2. Error grid analysis: Percentage of replicates within each zone of the Consensus Error Grid (Capillary)

Measured at the single study visit

## Overall study start date

01/02/2017

## Completion date

31/12/2029

# **Eligibility**

## Key inclusion criteria

- 1. Diagnosed with diabetes
- 2. ≥16 years of age

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

16 Years

#### Sex

Both

#### Target number of participants

The target is to enroll approximately 55 participants per study event

#### Key exclusion criteria

- 1. Participated in the study event already
- 2. Member of the site study team

#### Date of first enrolment

01/02/2017

#### Date of final enrolment

31/12/2028

## Locations

#### Countries of recruitment

England

**United Kingdom** 

# Study participating centre

Ipswich Hospital

United Kingdom IP4 5PD

Study participating centre
Oxford Centre for Diabetes, Endocrinology and Metabolism
United Kingdom
OX3 7LE

# Study participating centre St James's University Hospital United Kingdom LS9 7TF

Study participating centre Salford Royal Hospital United Kingdom M6 8HD

Study participating centre
North Manchester General Hospital
United Kingdom
M8 5RB

# Sponsor information

## Organisation

Abbott Diabetes Care Ltd

#### Sponsor details

Range Road Witney United Kingdom OX29 0YL

#### Sponsor type

Industry

#### **ROR**

https://ror.org/03wnay029

# Funder(s)

## Funder type

Industry

#### Funder Name

Abbott Diabetes Care Ltd

## **Results and Publications**

## Publication and dissemination plan

The purpose of this study is to monitor ongoing performance as part of a post-market surveillance program. Results are of limited interest to scientific or medical publications, however if the results highlight any interesting information a manuscript or abstract will be prepared.

#### Intention to publish date

31/12/2030

#### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from ADC\_Witney\_ClinicalAffairs@abbott.com.

#### IPD sharing plan summary

Available on request

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No